<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546856</url>
  </required_header>
  <id_info>
    <org_study_id>PI14/01208</org_study_id>
    <nct_id>NCT02546856</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients</brief_title>
  <acronym>ETIFIC</acronym>
  <official_title>Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Galdakao-Usansolo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carlos III Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Basque Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Galdakao-Usansolo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Heart Failure (HF) generates multiple hospital admissions and mortality, which&#xD;
      are reduced with the administration of Beta-Blocker (BB), Angiotensin Converting Enzyme&#xD;
      Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor&#xD;
      Antagonist (MRA) drugs (Level of Evidence A). The effect is dose-dependent. Nevertheless,&#xD;
      dosages are suboptimal. European Guidelines 2012 recommend close monitoring and up-titration&#xD;
      of drugs by HF nurses. Trials are needed to evaluate their effectiveness and safety.&#xD;
      Objective: To compare doses achieved by patients of BB, ACEI, ARB II and MRA in 4 months ( %&#xD;
      relative to target doses) in the intervention group (HF nurse) and in the control group (&#xD;
      cardiologist), adverse events, Left Ventricular Ejection Fraction (LVEF), New York Heart&#xD;
      Association (NYHA), 6 min. walking test, quality of life, Nt-proBNP, readmissions and&#xD;
      mortality. Hypothesis: Non-inferiority. Design: Multicenter randomized controlled trial. New&#xD;
      (&quot;de novo&quot;) HF patients with LVEF ≤ 40%, NYHA II-III, without contraindications to BB of 17&#xD;
      Spanish hospitals will be included. Intervention: The cardiologist prescribes drugs and,&#xD;
      driven by protocol, the HF nurse implements the up-titration. In the control group doses are&#xD;
      decided by the cardiologist clinical support and education being provided by nurses.&#xD;
      Variables: age, sex, education, psycho-social level, Cardio Vascular Risk Factors (CVRF),&#xD;
      NYHA, LVEF, ischemic cardiopathy., N-terminal pro B-type natriuretic peptide (Nt-proBNP),&#xD;
      6min. walking test, Creatinine/Glomerular Filtration Rate (GFR), Potassium (K), haemoglobin,&#xD;
      Blood Pressure (BP), Heart Rate (HR), mg./drug, European Heart Failure Self-Care Behaviour&#xD;
      Scale (EHFScBS), Minnesota Living with Heart Failure questionnaire (MLHFQ), European Quality&#xD;
      of life Scale (EQ-5D). Expected Results: If our hypothesis were confirmed, evidence would be&#xD;
      provided on the effectiveness of this healthcare management, that could be economically&#xD;
      evaluated in future studies. A qualitative study also will be undertaken to explore barriers&#xD;
      and facilitators to implementation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No apply&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BB % Relative Dose (Mean) With Regard to Target Dose</measure>
    <time_frame>4 months</time_frame>
    <description>BB mean Relative dose is the mean dose of betablockers achieved 4 months after starting titration, relative to target dose ( %) , which is the target dose of european heart failure guidelines for BB.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Worsening Renal Function (From Baseline to 4th Month)</measure>
    <time_frame>4 months</time_frame>
    <description>Number of participants with worsening renal function during the titration process (from baseline to 4 month) that could be associated to the titration process (Creatinine increase &gt;50% baseline creatinine or creatinine&gt;3mg/dl, or Estimated Glomerular Filtration&lt;25 ml/min/1.73 m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potassium (K) ≥5.5 Meq/l (From Baseline to 4 Month)</measure>
    <time_frame>4 months</time_frame>
    <description>Number of participants with Potassium≥ 5.5 meq/l during the titration process (from baseline to 4 month) that could be associated to this titration process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Symptomatic Hypotension (From Baseline to 4 Month)</measure>
    <time_frame>4 months</time_frame>
    <description>Description: Number of participants with symptomatic hypotension during the titration process (from baseline to 4 month) that could be associated to this titration process. Symptomatic hypotension defined as symptoms such as dizziness or light headedness, associated to hypotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Heart Rate (HR) &lt; 50 Beats Per Minute (From Baseline to 4 Month)</measure>
    <time_frame>4 months</time_frame>
    <description>Number of participants with Heart Rate (HR) &lt; 50 beats per minute during the titration process (from baseline to 4 month) , which could be associated to the titration process. (with or without symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Atrio Ventricular (AV) Block Due to Titration</measure>
    <time_frame>4 months</time_frame>
    <description>Number of patients with AV Block during the titration process, associated to the BB titration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Worsening of Heart Failure Signs and Symptoms</measure>
    <time_frame>4 months</time_frame>
    <description>Number of patients with worsening of heart failure signs and symptoms during the titration process ( from baseline to 4 month) which could be associated to the titration process.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Admissions Due to Titration</measure>
    <time_frame>4 months</time_frame>
    <description>Number of patients with admissions due to titration ( not due to other causes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients: Mortality Due to Titration</measure>
    <time_frame>4 months</time_frame>
    <description>Number of patients: Mortality due to titration ( not due to other causes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Paticipants With Drug Stop (Some Titration Drug Withdrawal Due to Intolerance, no Need or Change to Other Treatment)</measure>
    <time_frame>4 months</time_frame>
    <description>number of paticipants with drug Stop ( withdrawal) that occur during the titration process that could be due to an adverse event. ( it can be not only due to an adverse event but because there is no need of this drug or its substitution for another kind of drug)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in % Left Ventricular Ejection Fraction</measure>
    <time_frame>6 months</time_frame>
    <description>Change in % Left Ventricular Ejection Fraction (difference of change from baseline to 6 months between groups) Ejection fraction is a measurement of the percentage of blood leaving the heart each time it contracts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal Pro-B Type Natriuretic Peptide Improvement (Nt-proBNP)</measure>
    <time_frame>6 months</time_frame>
    <description>Nt-proBNP (N-terminal pro-B type natriuretic peptide) Improvement (Decrease) difference of change from baseline to 6 months between groups, mean (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walking Test</measure>
    <time_frame>6 months</time_frame>
    <description>6 minute walking test improvement ( change) meters.Improvement (difference of change from baseline to 6 months between groups Six minute walking test. Measurement of exercise capacity is an integral element in assessment of patients with cardiopulmonary disease. It provides information regarding functional capacity, response to therapy and prognosis across a range of chronic cardiopulmonary conditions. The six-minute walk test (6MWT) measures the distance (meters) an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants n(%) in New York Heart Association Functional Classification I,II,III,IV</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants class I-IV New York Heart Association (NYHA) functional classification, based on severity of symptoms and physical activity:&#xD;
NYHA I (better): No limitation of physical activity; NYHA II: Slight limitation of ordinary physical activity, breathlessness; NYHA III: marked limitation of physical activity. Comfortable at rest, but less than ordinary activity results in undue breathlessness, fatigue or palpitations; NYHA IV ( worse): unable to carry on any physical activity without discomfort.Symptoms at rest can be present. If any physical activity is undertaken discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: MLWHFQ</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life, measured by Minnesota Living with Heart Failure Questionnaire. Improvement (change) from baseline to 6 months.&#xD;
Minnesota Living With Heart Failure Questionnaire (MLWHFQ). The content of this questionnaire was selected to be representative of the ways heart failure and treatments can affect the key physical, emotional, social and mental dimensions of quality of life of patients with heart failure. It consist of 21-items with score 0-5. Final evaluation moves from 0 (none) to 105 (very much); a lower score means better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life Scale: EuroQol- 5 Dimension Index</measure>
    <time_frame>6 months</time_frame>
    <description>European Quality of Life Scale: EuroQol- 5 Dimension index (Range: 1 full health-0 death). It measures health status self-reported by the patient. It has 5 domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is divided into three levels: 1 no problem; 2 some or moderate problems; 3 extreme problems. The EuroQol Research Foundation converts this information into a single summary index, by applying a formula that attaches specific country values (called weights) to each of the levels in each dimension. The index is calculated by subtracting the mentioned weights from 1, the value for full health.&#xD;
We measured the EuroQol-5D index improvement (change) from baseline to 6 months.&#xD;
More information in: EQ-5D-3L-User-Guide_version-6.0 (1).pdf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Admissions Due to Heart Failure (HF)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with hospital admissions due to Heart Failure. From Baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Deaths</measure>
    <time_frame>6 months</time_frame>
    <description>Number of Patients with deaths due to Cardiovascular and non cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACEI % Relative Dose (Mean) With Regard to Target Dose</measure>
    <time_frame>4 Months</time_frame>
    <description>ACEI mean Relative dose is the mean dose of ACEI achieved 4 months after starting titration, relative to target dose (%) described in European guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARB % Relative Dose (Mean) With Regard to Target Dose</measure>
    <time_frame>4 months</time_frame>
    <description>ARB, angiotensin II receptor blockers, mean relative dose ( % to target dose). Target dose is described in European guidelines.&#xD;
Measured at 4 months after starting titration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRA % Relative Dose (Mean) With Regard to Target Dose</measure>
    <time_frame>4 months</time_frame>
    <description>MRA % relative dose (mean) is the mean dose achieved 4 months after starting titration with regard to target dose (%) described in european guidelines</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart Failure (HF) cardiologist up-titration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HF nurse up-titration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heart Failure (HF) nurse up-titration</intervention_name>
    <description>Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot;De Novo&quot; patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines with cardiologist prescription and support.</description>
    <arm_group_label>HF nurse up-titration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heart Failure (HF) cardiologist up-titration</intervention_name>
    <description>Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot;De Novo&quot; patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines. Drugs are prescribed and titrated by the cardiologist.</description>
    <arm_group_label>Heart Failure (HF) cardiologist up-titration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with &quot;de novo&quot; heart Failure and LVEF &lt;= 40% admitted in hospital, without&#xD;
             contraindications for BB prescription with cardiologist up-titration prescription and&#xD;
             without having achieved BB target dose previous discharge and signing informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for BB.&#xD;
&#xD;
          -  Living in a nursing home.&#xD;
&#xD;
          -  Life expectancy &lt; 6 months.&#xD;
&#xD;
          -  Unable to self-care or mental disease without caregiver.&#xD;
&#xD;
          -  Unable to weight&#xD;
&#xD;
          -  Without phone&#xD;
&#xD;
          -  Unable to go to clinic visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Juana Oyanguren, Nurse</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osakidetza-Servicio vasco de Salud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de usansolo-Galdakao</name>
      <address>
        <city>Usansolo</city>
        <state>Bizkaia</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Oyanguren J, García-Garrido L, Nebot Margalef M, Lekuona I, Comin-Colet J, Manito N, Roure J, Ruiz Rodriguez P, Enjuanes C, Latorre P, Torcal Laguna J, García-Gutiérrez S; ETIFIC7 research group. Design of a multicentre randomized controlled trial to assess the safety and efficacy of dose titration by specialized nurses in patients with heart failure. ETIFIC study protocol. ESC Heart Fail. 2017 Nov;4(4):507-519. doi: 10.1002/ehf2.12152. Epub 2017 Apr 3. Review.</citation>
    <PMID>29154427</PMID>
  </reference>
  <results_reference>
    <citation>Oyanguren J, Garcia-Garrido L, Nebot-Margalef M, Latorre-García P, Torcal-Laguna J, Comín-Colet J, Roure J, González-Costello J, Manito N, García-Pinilla JM, Sánchez-Paule Y, Varela-Román A, Moure M, Segovia-Cubero J, Soria T, Arana-Arri E, Lekuona I; Steering Committee on behalf of the ETIFIC research team group. Noninferiority of heart failure nurse titration versus heart failure cardiologist titration. ETIFIC multicenter randomized trial. Rev Esp Cardiol (Engl Ed). 2021 Jun;74(6):533-543. doi: 10.1016/j.rec.2020.04.016. Epub 2020 Jun 24. English, Spanish.</citation>
    <PMID>32591295</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <results_first_submitted>September 15, 2020</results_first_submitted>
  <results_first_submitted_qc>November 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2020</results_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Galdakao-Usansolo</investigator_affiliation>
    <investigator_full_name>Maria Juana Oyanguren Artola</investigator_full_name>
    <investigator_title>Heart Failure Nurse</investigator_title>
  </responsible_party>
  <keyword>Up-titration</keyword>
  <keyword>Nursing or Nurse</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02546856/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02546856/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Heart Failure (HF) Nurse Up-titration</title>
          <description>Intervention:The cardiologist prescribes drugs and the HF-nurse implements the up-titration, driven by protocol based on 2012 ESC HF guidelines, with cardiologist support.&#xD;
Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) drugs of Heart Failure &quot;De Novo&quot; Left Ventricular Ejection Fraction ≤ 40% Patients</description>
        </group>
        <group group_id="P2">
          <title>Heart Failure (HF) Cardiologist Up-titration</title>
          <description>Active Comparator:The cardiologist prescribes and decides dosage following a protocol based on 2012 ESC HF guidelines, with nursing clinical and educational support.&#xD;
Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) drugs of Heart Failure &quot;De Novo&quot; Left Ventricular Ejection Fraction ≤ 40% Patients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>4 Months Evaluation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Working or living abroad</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>reasons not due to titration</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>HF Unit not active in summer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>6 Months Evaluation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Working or living abroad</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>reasons not due to titration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Heart Failure (HF) Cardiologist Up-titration</title>
          <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; Left Ventricular Ejection Fraction ≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; Left Ventricular Ejection Fraction ≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; Left Ventricular Ejection Fraction≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; Left Ventricular Ejection Fraction ≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
        </group>
        <group group_id="B2">
          <title>HF Nurse Up-titration</title>
          <description>Patients, following a protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; Left Ventricular Ejection Fraction ≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; Left Ventricular Ejection Fraction ≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; Left Ventricular Ejection Fraction ≤ 40% Patients. Protocol based on 2012 ESC HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; Left Ventricular Ejection Fraction ≤ 40% Patients, . Protocol based on 2012 ESC HF guidelines.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="164"/>
            <count group_id="B3" value="320"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="164"/>
                    <count group_id="B3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.64" spread="12.25"/>
                    <measurement group_id="B2" value="61.88" spread="12.14"/>
                    <measurement group_id="B3" value="61.28" spread="12.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="164"/>
                    <count group_id="B3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="164"/>
                    <count group_id="B3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="164"/>
                    <count group_id="B3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>betablocker mean relative dose</title>
          <description>betablocker mean relative dose ( % to target dose) at baseline</description>
          <population>n considered for baseline doses In both groups: patients, who were at the time of measuring the achieved doses after titration, the 4th month. We evaluated the 4 month titration process made by HF cardiologist vs HF nurse. Patients who left the study did not receive this intervention.</population>
          <units>% to target dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="145"/>
                    <count group_id="B2" value="144"/>
                    <count group_id="B3" value="289"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.80" spread="20.6"/>
                    <measurement group_id="B2" value="34.81" spread="18.16"/>
                    <measurement group_id="B3" value="34.80" spread="19.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>left ventricular ejection fraction %</title>
          <description>Ejection fraction is a measurement of the percentage of blood leaving the heart each time it contracts.</description>
          <units>%of blood leaving the heart /beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="164"/>
                    <count group_id="B3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.45" spread="7.25"/>
                    <measurement group_id="B2" value="27.95" spread="6.69"/>
                    <measurement group_id="B3" value="27.71" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nt-proBNP</title>
          <description>Nt-proBNP (N-terminal pro-B type natriuretic peptide) at discharge mean (SD)</description>
          <population>other patients had BNP</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="139"/>
                    <count group_id="B2" value="145"/>
                    <count group_id="B3" value="284"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3001" spread="4041"/>
                    <measurement group_id="B2" value="3425" spread="5256"/>
                    <measurement group_id="B3" value="3217" spread="4697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6 minute walking test</title>
          <description>6 minute walking test, meters. Six minute walking test. Measurement of exercise capacity . It provides information regarding functional capacity, response to therapy and prognosis across a range of chronic cardiopulmonary conditions. The six-minute walk test (6MWT) measures the distance (meters) an individual is able to walk over a total of six minutes on a hard, flat surface.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="164"/>
                    <count group_id="B3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="370" spread="108"/>
                    <measurement group_id="B2" value="361" spread="102"/>
                    <measurement group_id="B3" value="366" spread="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with New York Heart Association (NYHA) I,II,III,IV</title>
          <description>Number of participants class I-IV New York Heart Association (NYHA) functional classification based on severity of symptoms and physical activity:&#xD;
NYHA I (better): No limitation of physical activity NYHA II: Slight limitation of ordinary physical activity, breathlessness NYHA III: marked limitation of physical activity. Comfortable at rest, but less than ordinary activity results in undue breathlessness, fatigue or palpitations NYHA IV ( worse): unable to carry on any physical activity without discomfort.Symptoms at rest can be present. If any physical activity, discomfort is increased.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="164"/>
                    <count group_id="B3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>NYHA I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Minnesota living with heart failure questionnaire</title>
          <description>Quality of Life measured by Minnesota Living With Heart Failure Questionnaire (MLWHFQ). The content of this questionnaire was selected to be representative of the ways heart failure and treatments can affect the key physical, emotional, social and mental dimensions of quality of life of patients with heart failure. It consist of 21-items with score 0-5. Final evaluation moves from 0 (none) to 105 (very much); a lower score means better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="164"/>
                    <count group_id="B3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.71" spread="22.21"/>
                    <measurement group_id="B2" value="50.8" spread="22.61"/>
                    <measurement group_id="B3" value="48.31" spread="22.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>European Quality of Life Scale: EuroQol- 5 Dimension index</title>
          <description>European Quality of Life Scale: EuroQol- 5 Dimension index (Range: 1 full health-0 death). It measures health status self-reported by the patient. It has 5 domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is divided into three levels: 1 no problem; 2 moderate problems; 3 extreme problems. This information is converted into a single summary index, by applying a formula that attaches specific country values to each of the levels in each dimension, that are subtracted from 1 (the full health). EQ-5D-3L-User-Guide_version-6.0 (1).pdf</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="156"/>
                    <count group_id="B2" value="164"/>
                    <count group_id="B3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.75" spread="0.24"/>
                    <measurement group_id="B2" value="0.73" spread="0.23"/>
                    <measurement group_id="B3" value="0.74" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ACEI mean relative dose</title>
          <description>angiotensin-converting enzyme inhibitors mean relative dose ( % to target dose described in european heart failure guidelines)</description>
          <population>n considered to calculate the mean baseline doses of ACEI in both groups: only the patients who received a prescription at baseline were included in the analysis.&#xD;
Every patient was prescribed betablocker but not ACEI. Alternatively It was possible to be prescribed ARB/sacubitril-valsartan or nothing</population>
          <units>% to target dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="121"/>
                    <count group_id="B2" value="118"/>
                    <count group_id="B3" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.13" spread="25.38"/>
                    <measurement group_id="B2" value="45.92" spread="30.06"/>
                    <measurement group_id="B3" value="43.04" spread="27.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angiotensin II Receptor Blockers (ARB) mean relative dose</title>
          <description>ARB, angiotensin II receptor blockers, mean relative dose ( % to target dose).Target dose is described in European guidelines. Measured at baseline.</description>
          <population>n considered to calculate the mean baseline doses of ARA in both groups: only the patients who received a prescription at baseline were included in the analysis.&#xD;
Every patient was prescribed betablocker but not ARB. Alternatively It was possible to be prescribed ACEI/sacubitril-valsartan or nothing</population>
          <units>% to target dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.20" spread="20.63"/>
                    <measurement group_id="B2" value="29.15" spread="14.99"/>
                    <measurement group_id="B3" value="33.84" spread="17.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MRA mean relative dose</title>
          <description>mineralocorticoid-receptor antagonists mean relative dose (% to target dose described in european heart failure guidelines)</description>
          <population>n for MRA baseline doses in both groups: patients, who were at the time of measuring the achieved doses after titration, the 4th month and had a prescription during the titration period at any time.&#xD;
Every patient was prescribed betablocker but not MRA. It was possible not having the need of its prescription.</population>
          <units>% to target dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="127"/>
                    <count group_id="B2" value="125"/>
                    <count group_id="B3" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.18" spread="33.00"/>
                    <measurement group_id="B2" value="61.4" spread="33.52"/>
                    <measurement group_id="B3" value="62.30" spread="33.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BB % Relative Dose (Mean) With Regard to Target Dose</title>
        <description>BB mean Relative dose is the mean dose of betablockers achieved 4 months after starting titration, relative to target dose ( %) , which is the target dose of european heart failure guidelines for BB.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; Left Ventricular ejection Fraction ≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; Left Ventricular ejection Fraction ≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; Left Ventricular ejection Fraction ≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; Left Ventricular ejection Fraction ≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; Left Ventricular ejection Fraction (EF) ≤ 40% Patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients. Protocol based on 2012 ESC HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients. Protocol based on 2012 ESC HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients. Protocol based on 2012 ESC HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>BB % Relative Dose (Mean) With Regard to Target Dose</title>
          <description>BB mean Relative dose is the mean dose of betablockers achieved 4 months after starting titration, relative to target dose ( %) , which is the target dose of european heart failure guidelines for BB.</description>
          <units>percentage of target dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.29" spread="31.3"/>
                    <measurement group_id="O2" value="71.09" spread="31.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For the hypothesis that the relative dose of BBs would reach 52% by the end of the study and using an equivalence margin of 7%, we would need 157 patients per group for an alpha level of significance of 0.05 and a statistical power of 80% (beta of 0.80).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.5</ci_lower_limit>
            <ci_upper_limit>22.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Worsening Renal Function (From Baseline to 4th Month)</title>
        <description>Number of participants with worsening renal function during the titration process (from baseline to 4 month) that could be associated to the titration process (Creatinine increase &gt;50% baseline creatinine or creatinine&gt;3mg/dl, or Estimated Glomerular Filtration&lt;25 ml/min/1.73 m2)</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Worsening Renal Function (From Baseline to 4th Month)</title>
          <description>Number of participants with worsening renal function during the titration process (from baseline to 4 month) that could be associated to the titration process (Creatinine increase &gt;50% baseline creatinine or creatinine&gt;3mg/dl, or Estimated Glomerular Filtration&lt;25 ml/min/1.73 m2)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.52</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentages</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.33</ci_lower_limit>
            <ci_upper_limit>6.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potassium (K) ≥5.5 Meq/l (From Baseline to 4 Month)</title>
        <description>Number of participants with Potassium≥ 5.5 meq/l during the titration process (from baseline to 4 month) that could be associated to this titration process</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potassium (K) ≥5.5 Meq/l (From Baseline to 4 Month)</title>
          <description>Number of participants with Potassium≥ 5.5 meq/l during the titration process (from baseline to 4 month) that could be associated to this titration process</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.31</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentages</param_type>
            <param_value>2.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>6.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Symptomatic Hypotension (From Baseline to 4 Month)</title>
        <description>Description: Number of participants with symptomatic hypotension during the titration process (from baseline to 4 month) that could be associated to this titration process. Symptomatic hypotension defined as symptoms such as dizziness or light headedness, associated to hypotension</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic Hypotension (From Baseline to 4 Month)</title>
          <description>Description: Number of participants with symptomatic hypotension during the titration process (from baseline to 4 month) that could be associated to this titration process. Symptomatic hypotension defined as symptoms such as dizziness or light headedness, associated to hypotension</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.85</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>5.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Heart Rate (HR) &lt; 50 Beats Per Minute (From Baseline to 4 Month)</title>
        <description>Number of participants with Heart Rate (HR) &lt; 50 beats per minute during the titration process (from baseline to 4 month) , which could be associated to the titration process. (with or without symptoms)</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines with cardiologist prescription and support.&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Heart Rate (HR) &lt; 50 Beats Per Minute (From Baseline to 4 Month)</title>
          <description>Number of participants with Heart Rate (HR) &lt; 50 beats per minute during the titration process (from baseline to 4 month) , which could be associated to the titration process. (with or without symptoms)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.44</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentages</param_type>
            <param_value>2.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>7.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Atrio Ventricular (AV) Block Due to Titration</title>
        <description>Number of patients with AV Block during the titration process, associated to the BB titration</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients,. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Atrio Ventricular (AV) Block Due to Titration</title>
          <description>Number of patients with AV Block during the titration process, associated to the BB titration</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Worsening of Heart Failure Signs and Symptoms</title>
        <description>Number of patients with worsening of heart failure signs and symptoms during the titration process ( from baseline to 4 month) which could be associated to the titration process.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients. Protocol based on 2012 ESC HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines.&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients,. Protocol based on 2012 ESC HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Worsening of Heart Failure Signs and Symptoms</title>
          <description>Number of patients with worsening of heart failure signs and symptoms during the titration process ( from baseline to 4 month) which could be associated to the titration process.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.56</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentages</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>3.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Admissions Due to Titration</title>
        <description>Number of patients with admissions due to titration ( not due to other causes)</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patient. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Admissions Due to Titration</title>
          <description>Number of patients with admissions due to titration ( not due to other causes)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients: Mortality Due to Titration</title>
        <description>Number of patients: Mortality due to titration ( not due to other causes)</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients: Mortality Due to Titration</title>
          <description>Number of patients: Mortality due to titration ( not due to other causes)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Paticipants With Drug Stop (Some Titration Drug Withdrawal Due to Intolerance, no Need or Change to Other Treatment)</title>
        <description>number of paticipants with drug Stop ( withdrawal) that occur during the titration process that could be due to an adverse event. ( it can be not only due to an adverse event but because there is no need of this drug or its substitution for another kind of drug)</description>
        <time_frame>4 months</time_frame>
        <population>Participants analyzed are only participants with drug withdrawal</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients,. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Paticipants With Drug Stop (Some Titration Drug Withdrawal Due to Intolerance, no Need or Change to Other Treatment)</title>
          <description>number of paticipants with drug Stop ( withdrawal) that occur during the titration process that could be due to an adverse event. ( it can be not only due to an adverse event but because there is no need of this drug or its substitution for another kind of drug)</description>
          <population>Participants analyzed are only participants with drug withdrawal</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>betablocker stop</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ACEI stop</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ARB stop</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MRA stop</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in % Left Ventricular Ejection Fraction</title>
        <description>Change in % Left Ventricular Ejection Fraction (difference of change from baseline to 6 months between groups) Ejection fraction is a measurement of the percentage of blood leaving the heart each time it contracts.</description>
        <time_frame>6 months</time_frame>
        <population>It has to be taken into account that in outcome mesasures the order of groups and their number of participants is reversed ( first HF cardiologist, second HF nurse) in regard to those in the participant flow. ( first HF nurse, second HF cardiologist)</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Change in % Left Ventricular Ejection Fraction</title>
          <description>Change in % Left Ventricular Ejection Fraction (difference of change from baseline to 6 months between groups) Ejection fraction is a measurement of the percentage of blood leaving the heart each time it contracts.</description>
          <population>It has to be taken into account that in outcome mesasures the order of groups and their number of participants is reversed ( first HF cardiologist, second HF nurse) in regard to those in the participant flow. ( first HF nurse, second HF cardiologist)</population>
          <units>percentage of blood expelled/each beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.46" spread="11.46"/>
                    <measurement group_id="O2" value="15.63" spread="13.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.96</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.69</ci_lower_limit>
            <ci_upper_limit>2.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>N-terminal Pro-B Type Natriuretic Peptide Improvement (Nt-proBNP)</title>
        <description>Nt-proBNP (N-terminal pro-B type natriuretic peptide) Improvement (Decrease) difference of change from baseline to 6 months between groups, mean (SD)</description>
        <time_frame>6 months</time_frame>
        <population>BNP was analysed in 11 patients of both groups, instead of Nt proBNP ( 121/117).</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines with cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>N-terminal Pro-B Type Natriuretic Peptide Improvement (Nt-proBNP)</title>
          <description>Nt-proBNP (N-terminal pro-B type natriuretic peptide) Improvement (Decrease) difference of change from baseline to 6 months between groups, mean (SD)</description>
          <population>BNP was analysed in 11 patients of both groups, instead of Nt proBNP ( 121/117).</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1577" spread="3225"/>
                    <measurement group_id="O2" value="-1593" spread="2733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.97</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>16.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-781</ci_lower_limit>
            <ci_upper_limit>748</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6 Minute Walking Test</title>
        <description>6 minute walking test improvement ( change) meters.Improvement (difference of change from baseline to 6 months between groups Six minute walking test. Measurement of exercise capacity is an integral element in assessment of patients with cardiopulmonary disease. It provides information regarding functional capacity, response to therapy and prognosis across a range of chronic cardiopulmonary conditions. The six-minute walk test (6MWT) measures the distance (meters) an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Walking Test</title>
          <description>6 minute walking test improvement ( change) meters.Improvement (difference of change from baseline to 6 months between groups Six minute walking test. Measurement of exercise capacity is an integral element in assessment of patients with cardiopulmonary disease. It provides information regarding functional capacity, response to therapy and prognosis across a range of chronic cardiopulmonary conditions. The six-minute walk test (6MWT) measures the distance (meters) an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.49" spread="74.20"/>
                    <measurement group_id="O2" value="57.76" spread="79.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.44</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.27</ci_lower_limit>
            <ci_upper_limit>25.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants n(%) in New York Heart Association Functional Classification I,II,III,IV</title>
        <description>Number of participants class I-IV New York Heart Association (NYHA) functional classification, based on severity of symptoms and physical activity:&#xD;
NYHA I (better): No limitation of physical activity; NYHA II: Slight limitation of ordinary physical activity, breathlessness; NYHA III: marked limitation of physical activity. Comfortable at rest, but less than ordinary activity results in undue breathlessness, fatigue or palpitations; NYHA IV ( worse): unable to carry on any physical activity without discomfort.Symptoms at rest can be present. If any physical activity is undertaken discomfort is increased.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants n(%) in New York Heart Association Functional Classification I,II,III,IV</title>
          <description>Number of participants class I-IV New York Heart Association (NYHA) functional classification, based on severity of symptoms and physical activity:&#xD;
NYHA I (better): No limitation of physical activity; NYHA II: Slight limitation of ordinary physical activity, breathlessness; NYHA III: marked limitation of physical activity. Comfortable at rest, but less than ordinary activity results in undue breathlessness, fatigue or palpitations; NYHA IV ( worse): unable to carry on any physical activity without discomfort.Symptoms at rest can be present. If any physical activity is undertaken discomfort is increased.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life: MLWHFQ</title>
        <description>Quality of Life, measured by Minnesota Living with Heart Failure Questionnaire. Improvement (change) from baseline to 6 months.&#xD;
Minnesota Living With Heart Failure Questionnaire (MLWHFQ). The content of this questionnaire was selected to be representative of the ways heart failure and treatments can affect the key physical, emotional, social and mental dimensions of quality of life of patients with heart failure. It consist of 21-items with score 0-5. Final evaluation moves from 0 (none) to 105 (very much); a lower score means better quality of life.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life: MLWHFQ</title>
          <description>Quality of Life, measured by Minnesota Living with Heart Failure Questionnaire. Improvement (change) from baseline to 6 months.&#xD;
Minnesota Living With Heart Failure Questionnaire (MLWHFQ). The content of this questionnaire was selected to be representative of the ways heart failure and treatments can affect the key physical, emotional, social and mental dimensions of quality of life of patients with heart failure. It consist of 21-items with score 0-5. Final evaluation moves from 0 (none) to 105 (very much); a lower score means better quality of life.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.01" spread="23.22"/>
                    <measurement group_id="O2" value="-26.37" spread="24.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.75</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.63</ci_lower_limit>
            <ci_upper_limit>4.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European Quality of Life Scale: EuroQol- 5 Dimension Index</title>
        <description>European Quality of Life Scale: EuroQol- 5 Dimension index (Range: 1 full health-0 death). It measures health status self-reported by the patient. It has 5 domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is divided into three levels: 1 no problem; 2 some or moderate problems; 3 extreme problems. The EuroQol Research Foundation converts this information into a single summary index, by applying a formula that attaches specific country values (called weights) to each of the levels in each dimension. The index is calculated by subtracting the mentioned weights from 1, the value for full health.&#xD;
We measured the EuroQol-5D index improvement (change) from baseline to 6 months.&#xD;
More information in: EQ-5D-3L-User-Guide_version-6.0 (1).pdf</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>European Quality of Life Scale: EuroQol- 5 Dimension Index</title>
          <description>European Quality of Life Scale: EuroQol- 5 Dimension index (Range: 1 full health-0 death). It measures health status self-reported by the patient. It has 5 domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is divided into three levels: 1 no problem; 2 some or moderate problems; 3 extreme problems. The EuroQol Research Foundation converts this information into a single summary index, by applying a formula that attaches specific country values (called weights) to each of the levels in each dimension. The index is calculated by subtracting the mentioned weights from 1, the value for full health.&#xD;
We measured the EuroQol-5D index improvement (change) from baseline to 6 months.&#xD;
More information in: EQ-5D-3L-User-Guide_version-6.0 (1).pdf</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.28"/>
                    <measurement group_id="O2" value="0.08" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.20</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Admissions Due to Heart Failure (HF)</title>
        <description>Number of patients with hospital admissions due to Heart Failure. From Baseline to 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Admissions Due to Heart Failure (HF)</title>
          <description>Number of patients with hospital admissions due to Heart Failure. From Baseline to 6 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.01</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in percentages</param_type>
            <param_value>-5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.7</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Deaths</title>
        <description>Number of Patients with deaths due to Cardiovascular and non cardiovascular causes</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Deaths</title>
          <description>Number of Patients with deaths due to Cardiovascular and non cardiovascular causes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>mortality due to cardiovascular causes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>mortality due to non cardiovascular causes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 5%</non_inferiority_desc>
            <p_value>0.71</p_value>
            <method>Chi-squared</method>
            <method_desc>Equivalence margin of 7%</method_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>2.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACEI % Relative Dose (Mean) With Regard to Target Dose</title>
        <description>ACEI mean Relative dose is the mean dose of ACEI achieved 4 months after starting titration, relative to target dose (%) described in European guidelines</description>
        <time_frame>4 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>ACEI % Relative Dose (Mean) With Regard to Target Dose</title>
          <description>ACEI mean Relative dose is the mean dose of ACEI achieved 4 months after starting titration, relative to target dose (%) described in European guidelines</description>
          <units>percentage of target dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.13" spread="30.4"/>
                    <measurement group_id="O2" value="72.61" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 7%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>16.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.7</ci_lower_limit>
            <ci_upper_limit>24.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ARB % Relative Dose (Mean) With Regard to Target Dose</title>
        <description>ARB, angiotensin II receptor blockers, mean relative dose ( % to target dose). Target dose is described in European guidelines.&#xD;
Measured at 4 months after starting titration.</description>
        <time_frame>4 months</time_frame>
        <population>During the titration process several patients that at baseline did not have ARB prescription were prescribed this drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>ARB % Relative Dose (Mean) With Regard to Target Dose</title>
          <description>ARB, angiotensin II receptor blockers, mean relative dose ( % to target dose). Target dose is described in European guidelines.&#xD;
Measured at 4 months after starting titration.</description>
          <population>During the titration process several patients that at baseline did not have ARB prescription were prescribed this drug.</population>
          <units>percentage of target dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.51" spread="33.7"/>
                    <measurement group_id="O2" value="44.48" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 7%</non_inferiority_desc>
            <p_value>0.93</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.1</ci_lower_limit>
            <ci_upper_limit>17.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRA % Relative Dose (Mean) With Regard to Target Dose</title>
        <description>MRA % relative dose (mean) is the mean dose achieved 4 months after starting titration with regard to target dose (%) described in european guidelines</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure (HF) Cardiologist Up-titration</title>
            <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
          </group>
          <group group_id="O2">
            <title>HF Nurse Up-titration</title>
            <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
          </group>
        </group_list>
        <measure>
          <title>MRA % Relative Dose (Mean) With Regard to Target Dose</title>
          <description>MRA % relative dose (mean) is the mean dose achieved 4 months after starting titration with regard to target dose (%) described in european guidelines</description>
          <units>percentage of target dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.47" spread="29.8"/>
                    <measurement group_id="O2" value="71.00" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin of 7%</non_inferiority_desc>
            <p_value>0.86</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>8.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline to 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Heart Failure (HF) Cardiologist Up-titration</title>
          <description>Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.&#xD;
HF cardiologist up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines&#xD;
HF cardiologist up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines</description>
        </group>
        <group group_id="E2">
          <title>HF Nurse Up-titration</title>
          <description>Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.&#xD;
HF nurse up-titration: Up-titration of Beta-Blocker (BB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 European Society of Cardiology (ESC) HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support&#xD;
HF nurse up-titration: Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure &quot; De Novo&quot; EF≤ 40% patients. Protocol based on 2012 ESC HF guidelines. Cardiologist prescription and support</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalizations due to cardiovascular cause</sub_title>
                <description>unplanned hospitalizations due to cardiovascular cause (not due to non cardiovascular cause)</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="145"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>heart rate &lt;50 bpm</sub_title>
                <description>heart rate &lt; 50 bpm, bradycardia possibly due to the titration process</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>symptomatic hypotension</sub_title>
                <description>symptomatic hypotension possibly due to the titration process</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="145"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>the implementation of ETIFIC in a single country; its recruitment characteristics, inclusion of de novo HF patients exclusively, relatively young patients and the low percentage of women and patients with ischemic heart disease.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Juana Oyanguren, Nursing graduate, Master in Heart Failure, CV Pathology and Thrombosis Specialist</name_or_title>
      <organization>Servicio de Cardiologıa, Hospital Universitario Galdakao-Usansolo, OSI Barrualde-Galdakao-Osakidetza, Servicio Vasco de Salud, Galdakao, Bizkaia, Spain .BIOCRUCES, Instituto de Investigacion Sanitaria, Bizkaia, Spain</organization>
      <phone>34 656780945</phone>
      <email>juanaoy@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

